 |
| Nathalie Agar, PhD |
Nathalie Agar, PhD, founding director of the Surgical Molecular Imaging Laboratory in the Department of Neurosurgery, was named co-principal investigator of the National Brain Tumor Society’s DNA Damage Response Consortium.
The consortium — which also comprises teams from St. Jude Children’s Research Hospital, New York University Grossman School of Medicine, the University of California San Francisco, Mayo Clinic, the University of Minnesota, and Dana-Farber Cancer Institute — aims to advance a new class of promising potential treatments that can target a brain tumor’s DNA damage response network. Agar, who is also the Brigham’s Daniel E. Ponton Distinguished Chair in Neurosurgery, was appointed co-PI with Ranjit Bindra, MD, PhD, of Yale Cancer Center.
Agar’s lab is a pioneer in the development and implementation of integrated biomolecular and drug imaging of tissue specimens through mass spectrometry. She brings critical skills in biomarker discovery, pharmacometabolomics, specimen preparation, and data analysis to the consortium.
The National Brain Tumor Society and the Bindra lab at Yale Cancer Center initially launched the consortium in early 2022, leveraging years of experience and expertise in DNA damage response and biomarker-driven precision medicine approaches to the initiative. The effort is bolstered by a partnership with IQVIA, a global provider of advanced analytics, technology solutions and clinical research services.
Founded in 1981, the National Brain Tumor Society is the largest patient advocacy organization in the United States committed to curing brain tumors and improving the lives of patients and families.
